🗞️Radiopharm banks US$2m in sales to American medical giant | Media covered by Business News. https://lnkd.in/enZhZapR
Radiopharm Theranostics
Biotechnology Research
A world-class platform of radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic uses.
About us
Radiopharm Theranostics is developing a world-class platform of radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic uses.
- Website
-
http://www.radiopharmtheranostics.com
External link for Radiopharm Theranostics
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Sydney
- Type
- Privately Held
- Founded
- 2021
- Specialties
- nuclearmedicine, therapeutic, diagnostics, biotechnology, biotech, cancerresearch, cancer, clinicaltrials, medtech, health, radioactivedrugs, drugdiscovery, breastcancer, lungcancer, neckcancer, pancreaticcancer, braincancer, glioblastoma, peptides, smallmolecules, monoclonalantibodies, antibodies, breastcancerimaging, patients, HER2, radiopharmaceuticals, and therapeutics
Locations
-
Primary
Sydney, AU
Employees at Radiopharm Theranostics
Updates
-
RAD is pleased to announce that it has received a payment of A$3.0 million (US$2.0 million) from Nasdaq listed Lantheus Holdings Inc: https://bit.ly/4c7EK3u This payment is in accordance with the preclinical assets transfer and development agreement announced on 20 June 2024. CEO & MD, Riccardo Canevari said “I am delighted with the confidence demonstrated by Lantheus in settling the transfer and development agreement and making this payment ahead of the shareholder meeting later this month. We are well advanced in our strategic planning with Lantheus and the collaboration between our two companies augers well for the future. #biotech #medtech
-
🗞️Radiopharm Theranostics Targets Nasdaq Listing | Media coverage by JustStocks. https://lnkd.in/gnxjyKCi #RAD #Radiopharm #ASX #ASXNews
Radiopharm Theranostics Targets Nasdaq Listing
https://juststocks.com.au
-
RAD is pleased to announce that it expects to obtain a secondary listing on the #Nasdaq Capital Market by the end of 2024: https://buff.ly/3Sswcgv The Company expects the SEC and Nasdaq to complete their respective review processes by late August and, when their processes are successfully completed, then the listing on Nasdaq would occur.
-
Radiopharm Theranostics reposted this
RAD is pleased to announce it has received clearance for its Investigational New Drug (IND) application with the US #FDA, for F18-Pivalate (RAD 101): https://buff.ly/3SiRH3e The IND approval is a clear recognition by the FDA of clinical data already generated for RAD 101 and is a significant milestone towards starting a Phase 2b multi-center trial for the imaging of brain metastases. #biotech #medtech
-
RAD is pleased to announce it has received clearance for its Investigational New Drug (IND) application with the US #FDA, for F18-Pivalate (RAD 101): https://buff.ly/3SiRH3e The IND approval is a clear recognition by the FDA of clinical data already generated for RAD 101 and is a significant milestone towards starting a Phase 2b multi-center trial for the imaging of brain metastases. #biotech #medtech
-
RAD is pleased to be presenting at 12:30PM AEST in today's ShareCafe Hidden Gems webinar. Register for free at: https://lnkd.in/emiABZRa
Friday's webinar will discuss battery minerals, radiopharmaceutical products and cancer treatments. Register now https://bit.ly/4cXvNKO to hear from QX Resources ASX: QXR, Radiopharm Theranostics ASX: RAD & Arovella Therapeutics ASX: ALA
Welcome! You are invited to join a webinar: ShareCafe - Hidden Gems Webinar . After registering, you will receive a confirmation email about joining the webinar.
us02web.zoom.us
-
RAD was featured in the latest edition of Rat's Rant by Nick Kelso, where he discussed our recent $70m placement and cornerstone investment from Lantheus, as well as our current clinical pipeline: https://buff.ly/3Y4f5FA #biotech #medtech #radiopharma #ASX
-
The first patient has been dosed with RAD 204 (PD-L1 nanobody) in a Phase 1 therapeutic trial at Wollongong Hospital: https://buff.ly/4eYJ1IW 16 patients previously dosed in Phase 1 diagnostic study demonstrated safety and effective biodistribution, and validate the strong potential for ¹⁷⁷Lu-RAD204 for the treatment of advanced NSCLC. #biotech